Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction

Navnath S. Gavande, Pamela Vandervere-Carozza, Akaash K. Mishra, Tyler L. Vernon, Katherine S. Pawelczak, John Turchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.

Original languageEnglish (US)
Pages (from-to)8055-8070
Number of pages16
JournalJournal of Medicinal Chemistry
Volume60
Issue number19
DOIs
StatePublished - Oct 12 2017

Fingerprint

Xeroderma Pigmentosum Group A Protein
Xeroderma Pigmentosum
DNA Repair
Solubility
DNA
A-Form DNA
Replication Protein A
Drug Design
DNA-Binding Proteins
Structure-Activity Relationship
Amides
Inhibitory Concentration 50
Esters
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. / Gavande, Navnath S.; Vandervere-Carozza, Pamela; Mishra, Akaash K.; Vernon, Tyler L.; Pawelczak, Katherine S.; Turchi, John.

In: Journal of Medicinal Chemistry, Vol. 60, No. 19, 12.10.2017, p. 8055-8070.

Research output: Contribution to journalArticle

Gavande, Navnath S. ; Vandervere-Carozza, Pamela ; Mishra, Akaash K. ; Vernon, Tyler L. ; Pawelczak, Katherine S. ; Turchi, John. / Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 19. pp. 8055-8070.
@article{cbc627cbf10a4e7a8e0093f6e1fa75ce,
title = "Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction",
abstract = "XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.",
author = "Gavande, {Navnath S.} and Pamela Vandervere-Carozza and Mishra, {Akaash K.} and Vernon, {Tyler L.} and Pawelczak, {Katherine S.} and John Turchi",
year = "2017",
month = "10",
day = "12",
doi = "10.1021/acs.jmedchem.7b00780",
language = "English (US)",
volume = "60",
pages = "8055--8070",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction

AU - Gavande, Navnath S.

AU - Vandervere-Carozza, Pamela

AU - Mishra, Akaash K.

AU - Vernon, Tyler L.

AU - Pawelczak, Katherine S.

AU - Turchi, John

PY - 2017/10/12

Y1 - 2017/10/12

N2 - XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.

AB - XPA is a unique and essential protein required for the nucleotide excision DNA repair pathway and represents a therapeutic target in oncology. Herein, we are the first to develop novel inhibitors of the XPA-DNA interaction through structure-guided drug design efforts. Ester derivatives of the compounds 1 (X80), 22, and 24 displayed excellent inhibitory activity (IC50 of 0.82 ± 0.18 μM and 1.3 ± 0.22 μM, respectively) but poor solubility. We have synthesized novel amide derivatives that retain potency and have much improved solubility. Furthermore, compound 1 analogs exhibited good specificity for XPA over RPA (replication protein A), another DNA-binding protein that participates in the nucleotide excision repair (NER) pathway. Importantly, there were no significant interactions observed by the X80 class of compounds directly with DNA. Molecular docking studies revealed a mechanistic model for the interaction, and these studies could serve as the basis for continued analysis of structure-activity relationships and drug development efforts of this novel target.

UR - http://www.scopus.com/inward/record.url?scp=85031277009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031277009&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b00780

DO - 10.1021/acs.jmedchem.7b00780

M3 - Article

C2 - 28933851

AN - SCOPUS:85031277009

VL - 60

SP - 8055

EP - 8070

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -